RO 743-5846/F04

DRUG4 trials

Sponsors

F. Hoffmann-La Roche AG

Conditions

Previously Untreated Advanced or Metastatic Non-Squamous Non−Small Cell Lung CancerResected Stage II-III Kirsten rat sarcoma virus oncogene homolog glycine 12 to Cysteine (KRAS G12C) -Positive Non-Small Cell Lung CancerSolid tumorsUntreated Advanced or Metastatic Non-Small Cell Lung Cancer

Phase 1

A Phase Ib/II, Open-Label, Multicenter Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib in Combination with Other Anti-Cancer Therapies in Patients with Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer with a KRAS G12C Mutation

RecruitingCTIS2023-507171-22-00

F. Hoffmann-La Roche AGUntreated Advanced or Metastatic Non-Small Cell Lung Cancer

Start: 2023-06-21Target: 116Updated: 2025-10-27

Phase 2

Tumor-Agnostic Precision Immuno-Oncology and Somatic Targeting Rational for You (TAPISTRY) Phase II Platform Trial

Active, not recruitingCTIS2023-507418-28-00

F. Hoffmann-La Roche AGSolid tumors

Start: 2021-03-15Target: 407Updated: 2025-12-09

Phase 3

A PHASE III, RANDOMIZED, OPEN-LABEL STUDY EVALUATING THE EFFICACY AND SAFETY OF DIVARASIB AND PEMBROLIZUMAB VERSUS PEMBROLIZUMAB AND PEMETREXED AND CARBOPLATIN OR CISPLATIN IN PATIENTS WITH PREVIOUSLY UNTREATED, KRAS G12C-MUTATED, ADVANCED OR METASTATIC NON-SQUAMOUS NON-SMALL CELL LUNG CANCER

RecruitingCTIS2024-518365-10-00

F. Hoffmann-La Roche AGPreviously Untreated Advanced or Metastatic Non-Squamous Non−Small Cell Lung Cancer

Start: 2025-10-28Target: 282Updated: 2026-01-13

A PHASE III, RANDOMIZED, OPEN-LABEL STUDY EVALUATING THE EFFICACY AND SAFETY OF DIVARASIB COMPARED WITH INVESTIGATOR’S CHOICE OF IMMUNOTHERAPY OR OBSERVATION IN PATIENTS WITH RESECTED STAGE II-III KRAS G12C-POSITIVE NON-SMALL CELL LUNG CANCER

Not yet recruitingCTIS2025-524263-21-01

F. Hoffmann-La Roche AGResected Stage II-III Kirsten rat sarcoma virus oncogene homolog glycine 12 to Cysteine (KRAS G12C) -Positive Non-Small Cell Lung Cancer

Target: 80Updated: 2026-08-28